Patent intelligence · US
US 8293272
Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
Patent details — US 8293272
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 23, 2012
- Expiration
- Oct 18, 2032
- Claims
- 10
- CPC classes
- A61K, A61K31/198, A61K9/1623, A61K9/1652
Quick answer
US 8293272 (Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts) is held by Globopharm Pharmazeutische Produktions-und Handelsgesellschaft m.b.H.. Status: granted. Granted Oct 23, 2012. Expires Oct 18, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/198, A61K9/1623, A61K9/1652, A61K9/2013, A61K9/2018
More from Globopharm Pharmazeutische Produktions-und Handelsgesellschaft m.b.H.
Related pharmaceutical patents in our USPTO index.
-
US 12310943
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
granted -
US 12297182
Compositions comprising an urolithin compound
granted -
US 12226455
Medical composition for treating cardiac wasting and cachexia
granted -
US 12220424
Compositions comprising nicotinamide riboside and a urolithin
granted -
US 12109190
Urolithins as immune response enhancers
granted -
US 12036205
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
granted -
US 12030863
Prodrugs of urolithins and uses thereof
granted -
US 11969408
Method for improving mitophagy in subjects
granted
Frequently asked questions
What is US patent 8293272?
US 8293272 (Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts) is held by Globopharm Pharmazeutische Produktions-und Handelsgesellschaft m.b.H.. Status: granted. Granted Oct 23, 2012. Expires Oct 18, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8293272?
Globopharm Pharmazeutische Produktions-und Handelsgesellschaft m.b.H. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 60 pharmaceutical patents for this assignee.
When does US 8293272 expire?
Our index shows an expiration date of Oct 18, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.